Immunic, Inc. Initiates CEO Search and Enters into Retention Agreement with Daniel Vitt

On April 7, 2026, Immunic, Inc. announced that it has commenced a formal search for a new Chief Executive Officer with commercial expertise in the multiple sclerosis space to lead the company's next stage of growth. In connection with this transition, the company entered into a Retention Bonus Agreement with current CEO Daniel Vitt. Under the terms of the agreement, Mr. Vitt is eligible to receive a lump-sum retention bonus of $670,000, provided he remains employed through the 91st day following the hiring of a new CEO. The agreement is intended to ensure leadership continuity during the search process and facilitate Mr. Vitt's potential transition into a new 'C-Suite' role focused on scientific strategy and portfolio advancement. If Mr. Vitt is terminated without cause or resigns for good reason before the retention date, the bonus remains payable. The payment will be credited against any future cash severance obligations under his existing employment agreements.